Neluxicapone (INNTooltip International Nonproprietary Name) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024.[1][2][3] The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone.[4][3] COMT inhibitors are used in conjunction with levodopa in the treatment of Parkinson's disease.[4] Neluxicapone was first described in the literature by 2018.[3][1] Its INNTooltip International Nonproprietary Name was designated by the World Health Organization (WHO) in 2019.[2]

References

  1. ^ a b The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2018 (StemBook2018) (PDF). World Health Organization. 2018. No. WHO/EMP/RHT/TSN/2018.1. -capone catechol-O-methyltransferase (COMT) inhibitors. entacapone (65), nebicapone (96), neluxicapone (119), nitecapone (62), opicapone (103), tolcapone (66)
  2. ^ a b World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81" (PDF). WHO Drug Information. 33 (1): 43–133.
  3. ^ a b c "Neluxicapone". PubChem. U.S. National Library of Medicine. Retrieved 8 October 2024.
  4. ^ a b Haasio K (2010). "Toxicology and safety of COMT inhibitors". International Review of Neurobiology. 95: 163–189. doi:10.1016/B978-0-12-381326-8.00007-7. ISBN 978-0-12-381326-8. PMID 21095462.


Allikas: http://en.wikipedia.org/wiki/Neluxicapone
No tags for this post.